Debunking Biologic Safety Myths in Elderly Psoriasis Patients

In "Debunking Biologic Safety Myths in Elderly Psoriasis Patients," the panel turns to how age of disease onset and age of the patient shape expectations for treatment.

Dr. Bunick asks Dr. Armstrong how early-onset versus late-onset psoriasis affects treatment response, referencing research she has contributed to on the topic. Armstrong explains that, at a population level, earlier-onset disease tends to present more severely, but she is careful to distinguish age of onset from overall disease duration, since a patient can have late-onset disease of the same duration as one with early-onset disease. She notes that truly new-onset psoriasis appearing in a patient's seventies, eighties, or nineties is relatively uncommon, which makes her more vigilant during examination to rule out psoriasiform mimics, medication-related causes, or phenotypic drift. Despite this added diagnostic caution, Armstrong is clear that late onset does not lower her treatment goals; older patients deserve the same push toward clear or almost clear skin as younger ones.

Dr. Bunick then names a misconception he encounters often: that biologics are inherently more dangerous or unsafe in older patients. He argues the opposite is true, that these targeted therapies can make a tremendous, safe difference in older patients' lives. Armstrong builds on this point by noting that biologic medications typically carry minimal drug-drug interactions, a meaningful advantage in an elderly population where polypharmacy is common. Bunick adds that this same polypharmacy concern, ironically, often drives the underlying safety worry, when in reality many older patients are taking numerous medications to manage symptoms that a single effective psoriasis therapy could address directly. The panel agrees that reframing biologic safety for older adults, rather than defaulting to caution based on age alone, can meaningfully expand access to effective treatment for this population.

Up next, in "Access, Adherence, and Dosing Frequency in Older Psoriasis Patients," the experts return to the 72-year-old patient to weigh biologic options against her dexterity limitations and access to care.